Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis

Oncologist

Volumn 18, Issue 6, 2013, Pages 667-674

  Curtit, Elsa ^a,d,e,f   Nerich, Virginie ^b,d,e   Mansi, Laura ^a,d   Chaigneau, Loic ^a   Cals, Laurent ^a   Villanueva, Cristian ^a   Bazan, Fernando ^a   Montcuquet, Philippe ^a   Meneveau, Nathalie ^a   Perrin, Sophie ^b,d,e   Algros, Marie Paule ^c   Pivot, Xavier ^a,d,e,f  

^a Departments of Medical Oncology   (France)

^b Departments of Pharmacy   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^e INSERM   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Breast cancer; Estrogen receptor; Human epidermal growth factor receptor 2; Progesterone receptor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BIOPSY; BREAST CANCER; BREAST METASTASIS; CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE INTERVAL; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM;

BREAST CANCER; ESTROGEN RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84879488869     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0350     Document Type: Article

References (32)

1. Cardoso F, Costa A, Norton L et al. First international consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-252.
2. Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 2009;10:933-935.
3. Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breastcancer. Am J Surg 1979;137:260-262.
4. Brunn Rasmussen B, Kamby C. Immunohisto-chemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract 1989;185:856-859.
5. Wilking U, Karlsson E, Skoog Let al. HER2 status in a population-derived breast cancer cohort: Dis-cordancesduringtumorprogression. Breast Cancer Res Treat 2011;125:553-561.
6. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499-1504.
7. Balaton AL, Coindre JM, Collin F et al. Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breastcancer. Ann Pathol 1996;16:144-148.
8. Penault-Llorca F, Vincent-Salomon A, Bellocq JP et al. Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France. Ann Pathol 2012;30:357-373.
9. Liedtke C, Broglio K, Moulder Set al. Prognostic impact of discordance between triple-receptor measurementsinprimaryandrecurrentbreastcan-cer. Ann Oncol 2009;20:1953-1958.
10. Greenberg P, Hortobagyi G, Smith T et al. Longterm follow-upof patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
11. Pagani O, Senkus E, Wood W et al. International guidelines for management of metastatic breast cancer: Can metastatic breast cancer can be cured? J Natl Cancerlnst 2010;102:456-463.
12. Gong Y, Han EY, Guo M et al. Stabilityofestro-gen receptorstatusin breastcarcinoma: Acompar-ison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer2011;117:705-713.
13. Amir E, Ooi WS, Simmons C et al. Discordance between receptorstatus in primaryand metastatic breast cancer: An exploratory study of bone and bone marrow biopsies. Clin Oncol 2008;20:763-768.
14. Macfarlane R, Seal M, Speers Cet al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. The Oncologist 2012;17:172-178.
15. Broom RJ, Tang PA, Simmons C et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: Discordance rates between primaryand metastatic breast cancer. Anticancer Res 2009;29:1557-1562.
16. Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res2009;2:R75.
17. Thompson AM, Jordan LB, Quinlan Pet al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: The Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010;12:R92.
18. Hilton JF, Amir E, Hopkins S et al. Acquisition of metastatic tissue from patients with bone metasta-ses from breast cancer. Breast Cancer Res Treat 2011;129:761-765.
19. Curigliano G, Bagnardi V, Viale G et al. Should liver metastases of breast cancerbe biopsied to improve treatmentchoice? Ann Oncol 2011;22:2227-2233.
20. Guarneri V, Giovannelli S, Ficarra G et al. Comparison of HER-2and hormone receptorexpression in primary breast cancers and asynchronous paired metastases: Impact on patient management. The Oncologist 2008;13:838-844.
21. Amir E, Clemons M, Purdie CAet al. Tissuecon-firmation ofdisease recurrence in breastcancerpa-tients: Pooled analysis of multi-centre, multi disciplinary prospective studies. Cancer Treat Rev 2012;38:708-714.
22. Botteri E, Disalvatore D, Curigliano G et al. Biopsy of livermetastasis for women with breast cancer: Impact on survival. Breast 2012;21:284-288.
23. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30:2601-2608.
24. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation ofmetastaticdisease in patients with breastcancer. J Clin Oncol 2012;30:587-592.
25. Pusztai L, Viale G, Kelly CM et al. Estrogen and HER-2 receptor discordance between primary breastcancerand metastasis. The Oncologist 2010; 15:1164-1168.
26. Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: Is re-biopsy a necessity or a luxury? Curr Oncol Rep 2011;13:17-25.
27. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
28. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer2009;9:631-643.
29. Mukohara T. Mechanisms ofresistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 2011;102:1-8.
30. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-7491.
31. Hortobagyi GN. Toward individualized breast cancer therapy: Translating biological concepts to the bedside. The Oncologist 2012;17:577-584.
32. Dawood S, Gonzalez-Angulo AM. To biopsy or not to biopsy: Is that the onlyquestion? The Oncol-ogist2012;17:151-153.